ARTICLES BY LOUIS

• High Potency Service Providers: The Contenders And Pretenders

  2/28/2017

  Is your CMO as accomplished at handling high-potency (HP) compounds as you think? Perhaps you’d better learn to separate "the contenders from the pretenders.” Here’s how.

• The “Isle Of Difference” In Contract Development And Manufacturing

  2/24/2017

  On the way to Life Science Leader magazine’s annual CMO Leadership Awards in Manhattan, we detoured to the “Isle of Difference.” This is a location where service providers devise sales and marketing strategies to entice circling customers to put down anchors with them, instead of at a competitor’s shores. 

• Three Experiences Power A Non-Profit's Business Approach

  1/31/2017

  Jennifer Dent is all business. At a nonprofit organization. She thinks that's exactly how it’s supposed to be. She also shares the enthusiasm of a humanitarian on a mission. Reviewing three experiences in the career of Dent, president of BIO Ventures for Global Health (BVGH), one might think none of this should be the case.

• Vaccine Development Skating On Start-Ups

  1/26/2017

  Ernst Soethout formed Virtuvax last year to take advantage of and further propel vaccine development trends, the most important being: “Big Pharma is ‘outsourcing’ R&D.” That in turn is driving the formation of virtual vaccine companies.”

• What Are New Board Members Saying About Outsourcing?

  1/18/2017

  Leaders from Achaogen, Allergan, Genzyme, Pfizer and Shire have joined the Outsourced Pharma Advisory Board. Already, they've provided some bold analysis — and a few grams of guidance — on outsourcing drug development and manufacturing.

• Chemical Development From Cotton Candy To Pharmaceuticals

  1/12/2017

  Sriram Naganathan, Senior Director, Chemical Development, Dermira, wants to be know as the person who: Came, Learned, and Taught. “I believe," he says, “I ended up working at the two best places for me in the world to learn process chemistry, Pfizer and Roche.” Now he teaches Outsourced Pharma readers what you should know for drug development outsourcing.

• Are You The Future of Pharmaceutical Development?

  12/27/2016

  Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.

• Outsourcing 2017: Countries, Costs, And Some Concerns

  12/19/2016

  "Topic one for me during 2016 was the rather sudden realization that CMOs will not be able to carry us forward in the near term …” says Darren Dasburg, VP BioVentures – Biologics, Medimmune/AstraZeneca. He and other Outsourced Pharma Editorial Board members provide useful insight for the New Year.

• Drug Development In 2017: The Year Of The Middle Way

  12/13/2016

  I asked members of our Outsourced Pharma Editorial Board for their thoughts on the out-going and in-coming years. We start here with Takuya Seko, Corporate Officer, Executive Director, CMC-Production & CMC Research, Ono Pharmaceutical Co., Ltd., and Piet Houwen, Head of Biologics - External Manufacturing, Sanofi Genzyme.

• Thomas Jefferson Hasn't A Clue About Drug Development

  12/8/2016

  Understanding what went before, and the steadfast resolve to get to the future, are invaluable for reaching success in our industry. An illustrative and teaching example of this – including the past and future of outsourcing – is embodied in the people at a “thirty-year-old biotech.” They have little in common with Thomas Jefferson.